Study closed to enrollment

Inclusion Criteria:

• Life expectancy of at least 3 months
• Histologically- or cytologically-confirmed diagnosis of non-small cell lung cancer (NSCLC) that is PD-L1 positive per central laboratory review
• At least one bi-dimensional measurable lesion
• Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet
• Currently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first dose
• Subjects with previously-treated brain metastases can enroll in PN010 provided that their brain metastases have been treated and proven to be stable by MRI for at least 4 weeks based on RECIST 1.1, before initiating treatment in PN010
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• These methods of contraception or abstinence from heterosexual activity are required from the screening visit through 180 days after the last dose of docetaxel.
  • The 2 birth control methods can be either:2 barrier methods or 1 barrier method plus 1 hormonal method to prevent pregnancy.
  • The following birth control methods are allowed during the study: • Barrier methods: • Diaphragm • Condom • Copper IUD • Sponge • Spermicide • Hormonal method: • Hormonal contraceptives (such as the birth control pill) • Abstinence (no sex)

Exclusion Criteria:

• Prior therapy with docetaxel for NSCLC
• Receiving systemic steroid therapy within three days prior to the first dose of study treatment or receiving any other form of immunosuppressive medication
• Expected to require any other form of systemic or localized antineoplastic therapy while on trial
• History of allogeneic tissue/solid organ transplant
• Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of >30 Gray within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug
• Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial
• Known history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, and has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents
• Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment
• Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
• Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after last dose of pembrolizumab or 180 days after last dose of docetaxel